Skip to content Skip to footer
Blog AirwayDevelopment

Airway Development: Is Your Child Breathing Correctly?

Studies show that 3-12 percent of children snore, 15 percent wet the bed at age five, and 11 percent of ages four to seven have ADHD. Obstructive sleep apnea (OSA), characterized by apneic periods due to an underdeveloped airway, is associated with each condition. OSA manifests in bruxism, poor sleeping habits, bedwetting, ADHD, moodiness, an inability to concentrate, and diabetes. How…

Read More

Post 53 scaled

Vivos Therapeutics Announces New Revenue Stream Through Strategic Medical Billing Relationship with Nexus Dental Systems

New Collaboration to Increase Payer Reimbursements and Patient Access LITTLETON Colorado, Dec. 15, 2022 GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), today announced the creation of a new strategic collaboration with Nexus Dental Systems (“Nexus”), which Vivos expects to generate new revenues starting immediately. Vivos and Nexus believe their alliance…

Read More

Post 52

Vivos Therapeutics Provides Update on Second Quarter Earnings Delay

Delay Due to Technical Revenue Recognition Analysis and Unrelated to Overall Business Health LITTLETON Colorado, August 22, 2022 16:05 ET | Source: Vivos Therapeutics, Inc (GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. (NASDAQ: VVOS) (“Vivos”) is providing an update on the delay in announcing its second quarter 2022 financial results. “We are disappointed it is taking longer than usual…

Read More

Post 51

Vivos Therapeutics to Reschedule Second Quarter 2022 Financial Results Conference Call

August 15, 2022 07:30 ET | Source: Vivos Therapeutics, Inc LITTLETON Colorado, Aug. 15, 2022 Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (OSA) and snoring in adults, today announced that it will reschedule…

Read More

Post 50

Vivos Therapeutics Schedules Second Quarter 2022 Financial Results Conference Call

Call Scheduled for Monday, August 15, 2022 at 5:00 pm ET LITTLETON Colorado, Aug. 09, 2022  Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (OSA) and snoring in adults, today announced that it…

Read More

Post 49

Vivos Therapeutics Announces Multiple Regulatory Clearances in Australia for Its Entire Line of Oral Appliances

Australia clears Vivos technology to treat obstructive sleep apnea for all ages and regardless of severity in broad regulatory win. LITTLETON Colorado, July, 14, 2022 (BUSINESS WIRE)–Vivos Therapeutics, Inc. (NASDAQ: VVOS) is pleased to announce that it has received multiple Class I clearances by the Therapeutic Goods Administration for multiple indications to include the treatment of snoring and…

Read More

Post 48 scaled

Vivos Therapeutics Announces Exclusive Distribution Agreement with GM Instruments, Ltd. for the U.S. and Canada

Effectively Immediately, Vivos to be Exclusive Distributor for Novel Diagnostic Equipment to Evaluate Nasal Breathing and Function in Dental Patients with Sleep and Breathing Issues LITTLETON Colorado, June, 29, 2022 (GLOBE NEWSWIRE) — — Vivos Therapeutics, Inc. (NASDAQ: VVOS) (“Vivos” or “the Company”), a revenue-stage medical technology company focused on developing innovative treatments for patients suffering from dentofacial…

Read More